Robust negotiations between biopharmaceutical companies and insurers often result in significant rebates and discounts. According to a recent study from the Berkeley Research Group, more than a third of the list price for brand medicines is rebated back to payers and the supply chain.
However, unlike care received at an in-network hospital or physician’s office, negotiated discounts for medicines are not shared with patients with high deductibles or coinsurance. A new analysis from Amundsen Consulting found more than half of commercially insured patients’ out-of-pocket spending for brand medicines is based on the full list price.
Insurers should share more of these rebates with patients. Providing access to discounted prices at the point-of-sale could dramatically lower patients’ out-of-pocket costs.
Get the facts and find out where the discounts are going.